Welcome
Support Centre
11 October 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A multicentre randomised trial of short neo-adjuvant chemotherapy (VAPEC-B) plus involved field radiotherapy (MIT) versus mantle radiotherapy
ISRCTN ISRCTN56416473
ClinicalTrials.gov identifier
Public title A multicentre randomised trial of short neo-adjuvant chemotherapy (VAPEC-B) plus involved field radiotherapy (MIT) versus mantle radiotherapy
Scientific title
Acronym N/A
Serial number at source LY07
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Lung (non-small cell) cancer
Participants - inclusion criteria 1. Patients aged between 16 and 75 years
2. Histologically proven Hodgkin's disease, stage IA or IIA with no mediastinal bulk
3. No previous treatment
4. No previous malignancy other than basal cell carcinoma or cervical intra-epithelial neoplasms
5. No concurrent illness which would contraindicate chemotherapy or radiotherapy
6. Not documented evidence of Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)
Participants - exclusion criteria If Hodgkin's disease is below the diaphragm only, patients are not eligible for this trial
Anticipated start date 01/01/1995
Anticipated end date 26/06/2001
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions 1. VAPEC-B Regimen: Minimal initial chemotherapy therapy involving vincristine, adriamycin, etoposide, cyclophosphamide and bleomycin, followed by involved field radiotherapy
2. Control Regimen: Mantle radiotherapy
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Cancer Research UK
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email register@ctu.mrc.ac.uk
Sponsor Cancer Research UK (CRUK) (UK)
  Address PO Box 123
Lincoln's Inn Fields
  City/town London
  Zip/Postcode WC2A 3PX
  Country United Kingdom
  Tel +44 (0)20 7317 5186
  Fax +44 (0)20 7487 4302
  Email kate.law@cancer.org.uk
  Sponsor website: http://www.cancer.org.uk
Date applied 01/07/2001
Last edited 27/05/2008
Date ISRCTN assigned 01/07/2001
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central